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Abstract Only a few Methyl-[
11C]-L-methionine (MET)
positron emission tomography (PET) studies have focused
on children and young adults with brain neoplasm. Due to
radiation exposure, long scan acquisition time, and the need
for sedation in young children MET-PET studies should be
restricted to this group of patients when a decision for fur-
ther therapy is not possible from routine diagnostic proce-
dures alone, e.g., structural imaging. We investigated the
diagnostic accuracy of MET-PET for the differentiation
betweentumorousandnon-tumorouslesionsinthisgroupof
patients. Forty eight MET-PET scans from 39 patients aged
from 2 to 21 years (mean 15 ± 5.0 years) were analyzed.
The MET tumor-uptake relative to a corresponding control
region was calculated. A receiver operating characteristic
(ROC) was performed to determine the MET-uptake value
that best distinguishes tumorous from non-tumorous brain
lesions. A differentiation between tumorous (n = 39) and
non-tumorous brain lesions (n = 9) was possible at a
threshold of 1.48 of relative MET-uptake with a sensitivity
of 83% and a speciﬁcity of 92%, respectively. A differen-
tiation between high grade malignant lesions (mean
MET-uptake = 2.00 ± 0.46) and low grade tumors (mean
MET-uptake = 1.84 ± 0.31) was not possible. There was a
signiﬁcant difference in MET-uptake between the histologi-
cally homogeneous subgroups of astrocytoma WHO grade II
and anaplastic astrocytoma WHO grade III (P = 0.02).
MET-PET might be a useful tool to differentiate tumorous
from non-tumorous lesions in children and young adults
when a decision for further therapy is difﬁcult or impossible
from routine structural imaging procedures alone.
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Introduction
Methyl-[
11C]-L-methionine (MET) positron emission
tomography (PET) is a well established method in the
diagnosis and management of adult patients suffering from
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DOI 10.1007/s11060-009-9953-xbrain tumors. Besides less common tumors of the cranial
cavity (e.g., embryogenic tumors, glioneural tumors, lym-
phomas, meningiomas) MET is incorporated into malignant
gliomas (e.g., anaplastic astrocytoma, anaplastic oligoastr-
ocytoma, anaplastic oligodendroglioma, glioblastoma mul-
tiforme), even in low grade gliomas (e.g., WHO-grade II
astrocytoma),anditisemployedinthemanagementofthese
patients [1, 2]. MET is a sensitive tracer in tumor detection.
Inadults,itdifferentiatesbenignfrommalignantlesionswith
high sensitivity and speciﬁcity with comparatively low
background activity in normal brain tissue [1, 2]. MET-
uptake correlates to cell proliferation in cell culture [3], Ki-
67 expression [4], cell nuclear antigen expression [5] and
microvessel density [6], indicating its role as a marker for
active tumor proliferation and angiogenesis. In addition it
seems to be useful in monitoring chemotherapy in patients
with brain tumors [7, 8]. The main advantage of amino acid
tracers when compared to [
18F]-2-ﬂuoro-2-deoxy-D-glucose
(FDG) is the excellent delineation of tumors extent [9].
Despite this good imaging properties of MET-PET only
a few studies have focused on children and young adults
with brain neoplasms [10–12]. Pirotte and co-workers
provided evidence that MET- and FDG-PET improves the
diagnostic yield in stereotactic brain biopsies and surgical
management of brain tumors in children [11, 13, 14].
In planning a PET scan for a child, various aspects need
consideration. For practical use and implementation of PET
in children see Borgwardt et al. [15]. Because molecular
imaging can not replace structural imaging modalities like
magnetic resonance imaging (MRI) or computed tomogra-
phy (CT), it is always a supplementary investigation with
radioactive exposure and comparatively long scan times. In
respect of the effective radiation dose, whole-body distri-
bution of FDG in children differed from adults: a greater
proportionoftheinjectedactivityaccumulatedintothebrain
and less was excreted to urine [16]. The dose of the injected
radionuclide has to be adjusted for body weight. In addition,
in children sedation or even general anesthesia especially in
veryyoungchildrenisnecessarytoavoidpatientmovement.
PETshouldberestrictedtochildrenwithbraintumorswhere
a clear decision for further therapy planning is not possible
from structural routine imaging alone.
We investigated the diagnostic accuracy of MET-PET
for the differentiation between tumorous and non-tumorous
lesions in this selected group of patients.
Patients and methods
Patients
Thirty-nine patients were included in the study. At the time
of MET-PET investigation, the mean age of all patients
was 15 ± 5.0 years (range 2–21 years). The patients were
referred to the PET-unit of the Max-Planck-Institute for
Neurological Research in Cologne, Germany because
decision from MRI ﬁndings was difﬁcult for further diag-
nostic procedures or therapy planning. A total of 48 MET-
PET scans were performed for all patients. Two or more
investigations were performed in 6 patients during follow
up. The purpose of the scan and potential risks were
explained to the patients or their legal guardians before
they gave their informed consent to the investigation.
In order to differentiate between children and young
adults, the threshold of age was set at 15 years. In the
literature, a clear deﬁnition of a young adult was not
available; therefore, the threshold of 15 years was set in the
middle of the period of life between 10 and 20 years,
which is the current deﬁnition of adolescence by the World
Health Organization (WHO). In our collective, at the time
of MET-PET imaging 17 patients were under the age of
15 years.
To evaluate the diagnostic accuracy of MET-PET for the
differentiation between tumorous and non-tumorous lesions
in this group of patients, routine diagnostic procedures like
histological examinations and follow-up structural imaging
(MRI or CT scans with contrast enhancing agents) were
performed. Follow-up structural imaging was performed to
conﬁrm or to exclude a change of the lesion size over the
course of the disease. Structural imaging procedures were
performed within the clinical routine periodically every
3–12 months, depending on the WHO-grade of the brain
tumor. E.g., a low-grade tumor was examined every
12 months, a WHO-grade IV tumor was examined every
3–6 months. Recurrence of a brain tumor was deﬁned
according to the Macdonald criteria (gadolinium enhance-
ment or tumor enlargement C25%) [17]. Furthermore, after
clinical deterioration or occurrence of new symptoms,
structural imaging was performed promptly. After MET-
PET imaging, the mean follow-up (imaging procedures like
MRI or CT and/or clinically) was 25.5 ± 43.3 months.
Additionally, clinical aspects like an asymptomatic course
of the disease, therapy response (e.g. anticonvulsive medi-
cation, corticosteroids) or a deterioration of symptoms were
considered as well.
In all patients in which a tumorous lesion (n = 31) was
suspected (primary tumor or recurrent/residual tumor), the
diagnosis was conﬁrmed histologically during the course of
the disease (Tables 1, 2). In patients with a non-tumorous
lesion (n = 8), the diagnosis was conﬁrmed histologically,
clinically, by imaging results (MRI or CT scan), or clini-
cally in combination with follow-up imaging results
(Table 1).
In 16 MET-PET scans of 15 patients (5 patients under
the age of 15 years) a primary brain tumor was suspected
on MRI (Table 3). In these patients MET-PET was
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123performed to conﬁrm MRI ﬁndings and to give additional
information about extent and dignity of the lesion.
Presence or absence of a primary tumor at the time of
MET-PET imaging (n = 16 in 15 patients) was conﬁrmed
(i) histologically after the MET-PET examination by sur-
gery or stereotactic biopsy (n = 8), (ii) clinically (n = 4),
(iii) or by follow-up MRI or CT scans (n = 3).
In 21 MET-PET scans of 20 patients (11 patients under
the age of 15 years) a recurrent or residual tumor was
suspected after therapy, but a clear differentiation from
posttherapeutic changes was not possible from MRI alone
(Table 4).
Presence or absence of a recurrent or residual tumor
with previously histologically conﬁrmed diagnosis at the
time of MET-PET imaging (n = 21 in 20 patients) was
conﬁrmed (i) by further histological diagnosis after surgery
or stereotactic biopsy (n = 5), (ii) clinically (n = 2), (iii)
by follow-up MRI or CT scans (n = 5), (iv) or clinically in
combination with follow-up imaging results (n = 8).
Additionally, 4 patients were examined initially when a
primary brain tumor was suspected on MRI and, afterward,
when a recurrent or residual tumor was suspected after
therapy (Table 5). In these 4 patients, 11 MET-PET scans
were performed (one patient of these 4 patients was under
the age of 15 years).
Presence of primary tumor and recurrent or residual
tumor, respectively, was conﬁrmed (i) both histologically
(n = 1), (ii) clinically and histologically (n = 1), (iii) or
clinically in combination with imaging results and histo-
logically (n = 2).
Most tumors were located in critical areas like basal
ganglia, midbrain, and brainstem or next to motor areas in
the pericentral region or speech relevant areas in the left
temporal lobe.
Methods
Altogether, 48 MET-PET studies of the 39 patients were
performed either on an ECAT EXACT HR or ECAT
EXACT scanner (Siemens-CTI, Knoxville, TN) [18, 19].
In one child a mild sedation and in four children a general
anesthesia was necessary to avoid patient movement. In
these cases, the children were under the age of 12 years.
11 MBq/kg bodyweight MET (maximum 740 MBq) were
injected intravenously. MET was synthesized according to
the method of Berger et al. [20]. Tracer accumulation was
recorded over 60 min directly after tracer injection or over
40 min beginning 20 min after tracer injection. The entire
brain was scanned in 47 transaxial slices. Summed activity
from 20 to 60 min after tracer injection was used for image
reconstruction. Scans were corrected for attenuation and
scatter. Spatial resolution was 6 mm or better in all
dimensions.
As described previously, a circular region of interest
(ROI) of 7 mm diameter was placed in the area of maxi-
mum MET-uptake [21]. Mean uptake of this ROI was
determined relative to a control region in the unaffected
hemisphere which was obtained by mirroring the ROI
along the medial sagittal plane. In midline or brainstem
lesions the reference ROI was placed in the fronto-lateral
cortex of the unaffected hemisphere.
To determine the relative MET-uptake value that best
distinguishes tumorous from non-tumorous brain lesions, a
receiver operating characteristic (ROC) analysis was per-
formed by varying the threshold of MET-uptake over the
whole range of values and calculating sensitivity and
speciﬁcity for each value.
For statistical analyses, SPSS version 10.0.7 (SPSS Inc.,
Chicago, Illinois) was used. Graphs were plotted with
SigmaPlot, version 7.0 (SPSS Inc., Chicago, Illinois).
Results
At a threshold of 1.48, relative MET-uptake differentiation
between tumorous (n = 39) and non-tumorous brain
lesions (n = 9) was possible with a sensitivity of 83% and
speciﬁcity of 92% (area under the curve = 0.94, 95%-
conﬁdence interval = 0.87–1.00; Fig. 1). At this threshold,
8 of 9 non-tumorous lesions were classiﬁed correctly by
using MET-PET imaging. The false-positive case was one
patient with a newly developed contrast enhancing lesion
in the pons 14 years after treatment of a medulloblastoma
with a MET-uptake of 1.53. This lesion disappeared slowly
without treatment in follow-up MRI examinations 1 and
4 months after the PET investigation. At a threshold
greater than 1.53, the speciﬁcity was 100% without false
positive ﬁndings.
Thirty-four of 39 conﬁrmed tumors were correctly
classiﬁed positive. False negative ﬁndings included two
pilocytic astrocytoma WHO grade I and two diffuse
astrocytoma WHO grade II. In one child with a suspected
medulloblastoma, several small areas with a slight MET-
uptake of 1.22 were observed. However, this uptake had to
be classiﬁed as false negative, because a manifest tumor
progression could be diagnosed 5 months later.
At a threshold of 1.48, relative MET-uptake differenti-
ation between tumorous and non-tumorous brain lesions
was possible in the group of patients under the age of
15 years (n = 17) with a sensitivity of 91% and a speci-
ﬁcity of 100%.
The mean MET-uptake in 17 high grade tumors [astrocy-
toma, oligoastrocytoma WHO grade III; ependymoblastoma;
glioblastoma, medulloblastoma, atypical teratoid rhabdoid
tumor (ATRT) WHO grade IV] was 2.00 ± 0.46. In
comparison to 22 low grade tumors [pilocytic astrocytoma,
J Neurooncol
123Table 1 Individual patient data
Pat. no. Age
[years]
Gender
(F = female
M = male)
Diagnosis WHO
grade
Localization Newly diagnosed
(ND)/recurrence
(REC)
Sx
a Rx
b Cx
c
1 17 F Pilocytic astrocytoma I Right fronto- parietal ND No No No
2 13 M Pilocytic astrocytoma I 3rd ventricle REC Yes No No
3 16 F Pilocytic astrocytoma I Left thalamus REC No Yes No
4 11 F Pilocytic astrocytoma I Right basal ganglia ND No No No
5 19 M Pilocytic astrocytoma I Sellar region REC No Yes No
6 12 M Pilocytic astrocytoma I Right basal ganglia REC No Yes No
7 14 F DNT I Left temporal ND No No No
8 17 M DIG I Left temporal ND No No No
9 10 M Astrocytoma II Right parietal ND No No No
10 8 M Astrocytoma II Left temporal ND No No No
11 21 F Astrocytoma II Left temporal ND/REC
d No No No
12 21 F Astrocytoma II Left precentral ND/REC
d No Yes No
13 20 M Astrocytoma II Left frontal REC Yes Yes Yes
14 4 F Astrocytoma II Quadrigeminal plate ND No No No
15 10 M Pleomorphic xanthoastrocytoma II Left temporal ND/REC
d Yes No No
16 13 M Ependymoma II Left cerebellum REC No Yes No
17 20 F Astrocytoma III Right thalamus REC No Yes No
18 21 F Astrocytoma III Right basal ganglia REC No Yes No
19 14 M Astrocytoma III Left pericentral REC Yes Yes No
20 14 F Astrocytoma III Right frontal REC Yes Yes No
21 19 F Oligoastrocytoma III Left temporo-parietal ND/REC
d Yes Yes Yes
22 21 F Oligoastrocytoma III Right internal capsula REC Yes Yes No
23 18 M Glioblastoma IV Left temporal REC Yes Yes Yes
24 12 F Glioblastoma IV Right thalamus REC Yes Yes Yes
25 20 F Medulloblastoma IV Left cerebellum REC Yes Yes Yes
26 10 F Medulloblastoma IV Right frontal REC Yes Yes No
27 21 M Medulloblastoma IV Pons REC Yes Yes Yes
28 8 F Medulloblastoma IV Right cerebellum REC Yes No Yes
29 11 F Ependymoblastoma IV Right fronto-temporal REC Yes Yes No
30 2 F ATRT IV Brainstem REC Yes No Yes
31 9 M ATRT IV Right temporo-occipital REC Yes No No
32 19 M Cortical malformation / Right temporal ND No No No
33 19 F Cortical malformation / Left temporal ND No No No
34 21 M Epilepsy / Right fronto-parietal ND No No No
35 18 F Pineal cyst / Pineal gland ND No No No
36 19 F ADEM / Right occipital ND No No No
37 18 F Multiple sclerosis / Left parieto-occipital ND No No No
38 20 F Multiple sclerosis / Left occipital ND No No No
39 18 M Stroke PCA / Left occipital ND No No No
Individual data of 39 children and young adults with suspected newly diagnosed or recurrent brain tumor who underwent MET-PET
DIG Desmoplastic infantile ganglioglioma, DNT dysembryoplastic neuroepithelial tumor, ATRT atypical teratoid rhabdoid tumor, ADEM acute
demyelinating encephalomyelitis, PCA posterior cerebral artery
a Surgery before MET-PET
b Radiation therapy before MET-PET
c Chemotherapy before MET-PET
d Patients were investigated at the time of ﬁrst diagnosis and at the time of suspected recurrence
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infantile ganglioglioma (DIG) WHO grade I; diffuse astro-
cytoma, pleomorphic xanthoastrocytoma WHO grade II], the
mean MET-uptake was lower (1.84 ± 0.31). However, a
differentiation between low grade and high grade tumorswas
not possible (Student’s t-test; P = 0.36). MET-uptake in the
different histological tumor types and WHO grades is sum-
marized in Table 6.
The MET-uptake differed signiﬁcantly (Student’s t-test;
P = 0.02) when focused on the histologically more homo-
geneous subgroup of diffuse astrocytoma WHO grade II
(1.69 ± 0.50) and anaplastic astrocytoma WHO grade III
(2.61 ± 0.73).
The MET-uptake in WHO grade I tumors, especially in
pilocytic astrocytomas (2.11 ± 0.88) was higher when
compared to WHO grade II astrocytomas (1.69 ± 0.50),
Table 2 Number of patients
with tumors of different
histological types and non-
tumorous lesions
Histological diagnosis and WHO grade Total Under age of 15 15–21 years
Histological diagnoses
Pilocytic astrocytoma I 6 3 3
Astrocytoma II 6 3 3
Pleomorphic xanthoastrocytoma II 1 1 0
Astrocytoma III 4 2 2
Oligoastrocytoma III 2 0 2
Glioblastoma IV 2 1 1
Medulloblastoma IV 4 2 2
Atypical teratoid rhabdoid tumor IV 2 2 0
Ependymoma II 1 1 0
Ependymoblastoma IV 1 1 0
DNT I 1 1 0
Desmoplastic infantile ganglioglioma I 1 0 1
Non-tumor lesions 8 0 8
Total 39 17 22
Table 3 Patients with a suspected primary brain tumor on MRI
# Pat.
no.
Age
[years]
Gender
(F = female
M = male)
Diagnosis WHO
grade
Localization Number of
MET-PET
scans [n]
Diagnosis
conﬁrmed by
1 1 17 F Pilocytic astrocytoma I Right fronto-parietal 1 1
2 4 11 F Pilocytic astrocytoma I Right basal ganglia 1 1
3 7 14 F DNT I Left temporal 1 1
4 8 17 M DIG I Left temporal 1 1
5 9 10 M Astrocytoma II Right parietal 1 1
6 10 8 M Astrocytoma II Left temporal 1 1
7 14 4 F Astrocytoma II Quadrigeminal plate 1 1
8 32 19 M Cortical malformation / Right temporal 1 2
9 33 19 F Cortical malformation / Left temporal 1 2
10 34 21 M Epilepsy / Right fronto-parietal 1 3
11 35 18 F Pineal cyst / Pineal gland 1 2
12 36 19 F ADEM / Right occipital 2 1
13 37 18 F Multiple sclerosis / Left parieto-occipital 1 3
14 38 20 F Multiple sclerosis / Left occipital 1 2
15 39 18 M Stroke PCA / Left occipital 1 3
In these patients PET was performed to conﬁrm MRI ﬁndings and to give additional information about extent and dignity of the lesion
Diagnosis was conﬁrmed (1) histologically after the MET-PET examination by surgery or stereotactic biopsy, (2) clinically, (3) or by follow-up
MRI or CT scans
J Neurooncol
123but the difference did not reach statistical signiﬁcance
(Student’s t-test; P = 0.28).
Discussion
Our ﬁndings suggest that MET-PET has diagnostic rele-
vance in a selected patient population including children
and young adults and is able to distinguish brain tumors
and non-tumorous brain lesions with a high sensitivity
(83%) and speciﬁcity (92%). Therefore, MET-PET may be
helpful especially in this group of patients when results of
structural routine diagnostic procedures are not sufﬁcient
enough to obtain a treatment decision and its planning.
Due to the reduced MET-uptake in healthy brain tissue
and, therefore, a increased contrast between normal brain
tissue and a tumorous lesion, MET-PET is superior to
FDG-PET in tumor detection and assessment of tumor
dimensions [9, 22, 23]. Utriainen and co-workers described
that 22 of 23 childhood brain tumors exhibited higher MET
accumulation in the tumor than in the adjacent brain tissue
[12]. This observation supports our ﬁndings and may
Table 4 Patients with suspected recurrent tumor after therapy in which a clear differentiation from posttherapeutic changes was not possible
from MRI alone
# Pat.
no.
Age
[years]
Gender
(F = female
M = male)
Diagnosis WHO
grade
Localization Number of
MET-PET
scans [n]
Diagnosis
conﬁrmed by
1 2 13 M Pilocytic astrocytoma I 3rd ventricle 1 3
2 3 16 F Pilocytic astrocytoma I Left thalamus 1 3
3 5 19 M Pilocytic astrocytoma I Sellar region 1 1
4 6 12 M Pilocytic astrocytoma I Right basal ganglia 1 3
5 13 20 M Astrocytoma II Left frontal 1
6 16 13 M Ependymoma II Left cerebellum 1 1
7 17 20 F Astrocytoma III Right thalamus 2 4
8 18 21 F Astrocytoma III Right basal ganglia 1 4
9 19 14 M Astrocytoma III Left pericentral 1 1
10 20 14 F Astrocytoma III Right frontal 1 3
11 22 21 F Oligoastrocytoma III Right internal capsula 1 4
12 23 18 M Glioblastoma IV Left temporal 1 4
13 24 12 F Glioblastoma IV Right thalamus 1 4
14 25 20 F Medulloblastoma IV Left cerebellum 1 4
15 26 10 F Medulloblastoma IV Right frontal 1 4
16 27 21 M Medulloblastoma IV Pons 1 1
17 28 8 F Medulloblastoma IV Right cerebellum 1 2
18 29 11 F Ependymoblastoma IV Right fronto-temporal 1 3
19 30 2 F ATRT IV Brainstem 1 2
20 31 9 M ATRT IV Right temporo-occipital 1 4
Diagnosis was conﬁrmed (1) histologically after the MET-PET examination by surgery or stereotactic biopsy, (2) clinically, (3) by follow-up
MRI or CT scans, (4) or clinically in combination with follow-up imaging results
Table 5 Patients with brain tumor which were examined initially when a primary brain tumor was suspected on MRI and, afterward, when a
recurrent or residual tumor was suspected after therapy
# Pat.
no.
Age
[years]
Gender
(F = female
M = male)
Diagnosis WHO
grade
Localization Number of
MET-PET
scans [n]
Diagnosis
conﬁrmed by
1 11 21 F Astrocytoma II Left temporal 2 4,1
2 12 21 F Astrocytoma II Left precentral 2 2,1
3 15 10 M Pleomorphic xanthoastrocytoma II Left temporal 5 1,1
4 21 19 F Oligoastrocytoma III Left temporo-parietal 2 4,1
Diagnosis was conﬁrmed (1) histologically after the MET-PET examination by surgery or stereotactic biopsy, (2) clinically, (3) by follow-up
MRI or CT scans, (4) or clinically in combination with follow-up imaging results
J Neurooncol
123indicate that MET-PET is not only highly sensitive but also
very speciﬁc.
However, four low grade tumors (two patients with
pilocytic astrocytoma and two patients with astrocytoma
WHO grade II) were classiﬁed false negative. Low MET-
uptake in a proportion of WHO grade II astrocytomas is a
known feature of this histological entity in adult patients
[21]. In contrast, in our study pilocytic astrocytoma
WHO grade I demonstrated relatively high MET-uptake
(2.11 ± 0.88) when compared to astrocytoma WHO grade
II (1.69 ± 0.50). This has also been observed in a previous
study [21]. Histopathological features of pilocytic astro-
cytoma include mitosis, microvascular proliferation and
inﬁltration, but are not signs of malignancy in this tumor
entity. In adult patients with gliomas, both mitotic activity
and increased vascularization correlate with high MET-
uptake, which may explain the high MET-uptake in pilo-
cytic astrocytomas [5, 6]. In the two patients with false
negative ﬁndings, low MET-uptake might be inﬂuenced by
a decreased degree of microvascular proliferation in the
pilocytic astrocytoma.
Additionally, MET-uptake in one patient with suspected
recurrent medulloblastoma was false negative in several
small areas (uptake ratio of 1.22) and tumor progression
occurred 5 months later. However, the uptake pattern of
small lesions may be underestimated due to partial volume
effects. Modern positron cameras like the ECAT EXACT
HR have a transaxial resolution of 3.6 mm full width at
half maximum, and, therefore small tumors might be hid-
den by normal brain uptake. Moderate MET-uptake was
also observed in embryonal tumors but all patients with
medulloblastoma suffered from recurrent tumor at the time
of examination. They had previously undergone chemo-
therapy and/or radiation therapy or they currently received
chemotherapy which might have inﬂuenced the tracer
uptake [7].
In contrast to ﬁndings in adult patients, MET-uptake of
low grade tumors did not differ signiﬁcantly from high
grade tumorous lesions [2, 21]. This observation is consis-
tent with the ﬁndings of Utriainen and colleagues [12] who
found no association between MET-uptake and malignancy
Fig. 1 ROC analysis of relative [
11C-MET]-uptake to differentiate
tumor from non-tumorous lesions
Table 6 Maximum MET-
uptake relative to corresponding
control region within tumors of
different histological types and
non tumorous lesions
A total of 48 PET investigations
were performed in 39 patients
a Number of MET-PET
investigations
b Standard deviation
Histological diagnosis and WHO grade nn
a Relative MET-uptake
(mean ± SD
b)
Relative MET uptake in different tumors
Pilocytic astrocytoma I 6 6 2.11 ± 0.88
Astrocytoma II 6 8 1.69 ± 0.50
Pleomorphic xanthoastrocytoma II 1 5 2.23 ± 0.48
Astrocytoma III 4 5 2.61 ± 0.73
Oligoastrocytoma III 2 3 2.61 ± 0.24
Glioblastoma IV 2 2 1.70 ± 0.55
Medulloblastoma IV 4 4 1.78 ± 0.55
Atypical teratoid rhabdoid tumor IV 2 2 1.36 ± 0.71
Ependymoma II 1 1 0.97
Ependymoblastoma IV 1 1 1.95
DNT I 1 1 2.04
Desmoplastic infantile ganglioglioma I 1 1 2.01
Non tumor lesions 8 9 1.04 ± 0.22
Total 39 48
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grade from high grade tumors in the whole group probably
is due to the confounding effect of high uptake in the pil-
ocytic astrocytomas, which are more frequent in children
than in adults. Even in adult patients, non-invasive grading
is difﬁcult when the histological subtype of the tumor is
unknown because tumors of different histological types and
grades show an overlapping pattern in MET-uptake [21].
E.g., oligodendrogliomas WHO grade II might exhibit a
MET-uptake comparable to those of anaplastic astrocytoma
WHO grade III [6, 21]. If the histological subtype is known,
non-invasive grading may be possible in children and young
adults, as indicated by the signiﬁcant difference of MET-
uptake between astrocytoma WHO grade II (1.69 ± 0.50)
and anaplastic astrocytoma WHO grade III (2.61 ± 0.73).
These data suggest that noninvasive diagnosis of malignant
progression in gliomas, which is of crucial prognostic and
therapeutic interest, may be possible with MET-PET.
However, intraindividual changes of MET-uptake in the
course of malignant tumor progression in this group of
patients have not been investigated systematically so far.
An important differential diagnosis of brain tumors with
a slightly increased uptake pattern are inﬂammatory
lesions. In our study a patient with ADEM showed a MET-
uptake of 1.45 which is only slightly lower than the
threshold of 1.48. This observation might be caused by a
disruption of the blood brain barrier due to the inﬂamma-
tion. A small number of acute inﬂammatory lesions with
mild MET-uptake have been observed in previous studies
[21, 24, 25].
Sequential MET-PET monitoring of the course of the
disease may be helpful in single cases. Figure 2 shows the
course of disease in a 10-year-old boy with a pleomorphic
xanthoastrocytoma WHO grade II. He was investigated
three times using MET-PET within 3 years. The tumor was
localized in the left temporal lobe and the patient suffered
from mild verbal amnesia at the time of ﬁrst diagnosis (left
image). In the histopathological work-up, the tumor yiel-
ded areas of increased Ki67-MIB1 proliferation index up to
10. Therefore, close monitoring was recommended. In
follow-up scans, the tumor recurred early 5 months after
initial surgery and 3 months after surgery of recurrent
tumor, respectively (Fig. 2). This demonstrates that even
repeated PET studies may be feasible in a single child
revealing important insight into the disease state.
In conclusion, MET-PET in children and young adults is
feasible and should be performed after critical consider-
ation of the indication for a MET-PET examination in this
group of patients when additional information is needed for
the differentiation from non-tumorous lesions before an
invasive procedure is initiated.
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